Evidence map›Paper›PMID 26510695›Full record

ArticleCirculation2015

Whither Anticoagulation in Pulmonary Arterial Hypertension? Conflicting Evidence REVEALed.

Robert P Frantz

Abstract readEditorialComment
In one paragraph

Article in Circulation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?Circulation. Cardiovascular quality and outcomes · 2018
    Pooled it
  2. Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR).The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Robert P FrantzFrom Mayo Clinic College of Medicine, Rochester, MN. frantz.robert@mayo.edu.
Mayo Clinic · US

Funding

Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).U01HL125205 · NHLBI · MAYO CLINIC ROCHESTER · PI FRANTZ, ROBERT PAUL · 2014 to 2018
$1.5M
NHLBI NIH HHS U01 HL125205
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease ManagementRegistriesAnticoagulantsFemaleHumansHypertension, PulmonaryMaleWarfarinAnticoagulantsWarfarinanticoagulantsEditorialshypertension, pulmonarytreatment outcomewarfarin

Identifiers

PMID26510695
PMCPMC4690770
OpenAlexW2308370547

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.